Clinical trial overview highlights radiopharmaceutical therapy protocols for recurrent meningioma, indicating a critical shift from compassionate use to rigorous evidence.
Theranostics and radiopharmaceutical therapies are rapidly transforming the medical landscape, and the neuro-oncology community is observing these developments with great interest. In a field characterized by a significant unmet clinical need for novel and effective treatment options to slow or
No takes yet. Share an insight, caveat, or question.
Tolboom et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: